120.94
price up icon0.17%   0.20
 
loading
Gilead Sciences Inc stock is traded at $120.94, with a volume of 5.40M. It is up +0.17% in the last 24 hours and up +6.40% over the past month. Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
See More
Previous Close:
$120.74
Open:
$120.415
24h Volume:
5.40M
Relative Volume:
0.80
Market Cap:
$150.06B
Revenue:
$28.80B
Net Income/Loss:
$6.31B
P/E Ratio:
24.06
EPS:
5.0273
Net Cash Flow:
$9.37B
1W Performance:
-1.52%
1M Performance:
+6.40%
6M Performance:
+13.93%
1Y Performance:
+36.22%
1-Day Range:
Value
$118.70
$121.14
1-Week Range:
Value
$118.70
$124.61
52-Week Range:
Value
$86.08
$124.61

Gilead Sciences Inc Stock (GILD) Company Profile

Name
Name
Gilead Sciences Inc
Name
Phone
(650) 574-3000
Name
Address
333 LAKESIDE DR, FOSTER CITY, CA
Name
Employee
17,600
Name
Twitter
@GileadSciences
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
GILD's Discussions on Twitter

Compare GILD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
120.94 149.82B 28.80B 6.31B 9.37B 5.0273
Drug Manufacturers - General icon
LLY
Lilly Eli Co
825.45 736.03B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
190.40 463.72B 92.15B 25.12B 18.18B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
227.99 403.22B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
130.36 254.84B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.49 217.76B 63.43B 16.42B 14.72B 6.4861

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Date Action Analyst Rating Change
Aug-19-25 Upgrade Daiwa Securities Neutral → Outperform
Aug-08-25 Upgrade Truist Hold → Buy
Jul-25-25 Upgrade Needham Hold → Buy
Apr-22-25 Resumed Cantor Fitzgerald Overweight
Mar-04-25 Reiterated Oppenheimer Outperform
Feb-18-25 Upgrade Deutsche Bank Hold → Buy
Feb-13-25 Upgrade DZ Bank Hold → Buy
Jan-10-25 Upgrade Morgan Stanley Equal-Weight → Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Nov-14-24 Initiated Citigroup Buy
Nov-08-24 Downgrade Maxim Group Buy → Hold
Oct-21-24 Upgrade Leerink Partners Market Perform → Outperform
Oct-17-24 Initiated Bernstein Outperform
Oct-07-24 Upgrade Wells Fargo Equal Weight → Overweight
Jul-08-24 Upgrade Raymond James Mkt Perform → Outperform
May-01-24 Reiterated Maxim Group Buy
Apr-24-24 Upgrade HSBC Securities Reduce → Hold
Feb-22-24 Downgrade Truist Buy → Hold
Nov-09-23 Initiated Deutsche Bank Hold
Sep-08-23 Upgrade BofA Securities Neutral → Buy
Sep-06-23 Initiated HSBC Securities Reduce
Jul-24-23 Reiterated Barclays Equal Weight
May-16-23 Upgrade BMO Capital Markets Market Perform → Outperform
Apr-28-23 Resumed Piper Sandler Overweight
Jan-03-23 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-13-22 Resumed BofA Securities Neutral
Dec-09-22 Downgrade DZ Bank Buy → Hold
Oct-31-22 Upgrade Barclays Underweight → Equal Weight
Oct-28-22 Reiterated BMO Capital Markets Market Perform
Oct-28-22 Reiterated Cowen Outperform
Oct-28-22 Reiterated JP Morgan Overweight
Oct-28-22 Reiterated Jefferies Buy
Oct-28-22 Upgrade Piper Sandler Neutral → Overweight
Oct-28-22 Reiterated RBC Capital Mkts Outperform
Oct-28-22 Upgrade Truist Hold → Buy
Oct-28-22 Reiterated Wells Fargo Equal Weight
Oct-04-22 Upgrade JP Morgan Neutral → Overweight
Jul-13-22 Initiated Cantor Fitzgerald Neutral
May-23-22 Initiated SVB Leerink Mkt Perform
Feb-28-22 Downgrade BMO Capital Markets Outperform → Market Perform
Feb-02-22 Reiterated BMO Capital Markets Outperform
Feb-02-22 Reiterated BofA Securities Neutral
Feb-02-22 Reiterated RBC Capital Mkts Outperform
Feb-02-22 Reiterated Truist Hold
Feb-02-22 Reiterated Wells Fargo Equal Weight
Jan-28-22 Upgrade Argus Hold → Buy
Jan-06-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-09-21 Resumed Wells Fargo Equal Weight
Dec-06-21 Initiated Goldman Neutral
Nov-19-21 Upgrade BMO Capital Markets Market Perform → Outperform
Nov-19-21 Resumed Piper Sandler Neutral
Oct-20-21 Resumed Cowen Outperform
Jul-30-21 Reiterated BMO Capital Markets Market Perform
Jul-30-21 Reiterated RBC Capital Mkts Outperform
Apr-01-21 Upgrade Bernstein Mkt Perform → Outperform
Mar-30-21 Upgrade Redburn Neutral → Buy
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-04-21 Upgrade Guggenheim Neutral → Buy
Nov-03-20 Resumed Morgan Stanley Equal-Weight
Oct-28-20 Initiated UBS Neutral
Sep-30-20 Resumed Jefferies Buy
Sep-15-20 Upgrade Maxim Group Hold → Buy
Jul-31-20 Reiterated Credit Suisse Neutral
Jul-31-20 Reiterated Morgan Stanley Equal-Weight
Jul-31-20 Reiterated Piper Sandler Overweight
Jul-31-20 Reiterated RBC Capital Mkts Outperform
Jul-31-20 Reiterated SunTrust Hold
Jul-31-20 Reiterated Wells Fargo Equal Weight
Jul-20-20 Upgrade Credit Suisse Underperform → Neutral
Jun-03-20 Upgrade SVB Leerink Mkt Perform → Outperform
May-26-20 Upgrade SunTrust Sell → Hold
May-01-20 Downgrade JP Morgan Overweight → Neutral
May-01-20 Downgrade Raymond James Outperform → Mkt Perform
May-01-20 Downgrade SunTrust Hold → Sell
Apr-27-20 Downgrade UBS Buy → Neutral
Apr-20-20 Downgrade BMO Capital Markets Outperform → Market Perform
Apr-20-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Downgrade CFRA Hold → Sell
View All

Gilead Sciences Inc Stock (GILD) Latest News

pulisher
Oct 24, 2025

Will Gilead Sciences Inc. stock remain a Wall Street favorite2025 Support & Resistance & Free Technical Pattern Based Buy Signals - newser.com

Oct 24, 2025
pulisher
Oct 24, 2025

What To Expect From Gilead In Q3 2025 (NASDAQ:GILD) - Seeking Alpha

Oct 24, 2025
pulisher
Oct 24, 2025

Gilead Sciences patents new PI3Kα inhibitors - BioWorld MedTech

Oct 24, 2025
pulisher
Oct 24, 2025

Gilead to Showcase Interim Long-Term Efficacy Data for Livdelzi® (Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - BioSpace

Oct 24, 2025
pulisher
Oct 23, 2025

Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - news.stocktradersdaily.com

Oct 23, 2025
pulisher
Oct 23, 2025

TD Cowen Raises Price Target for Gilead Sciences (GILD) to $125 | GILD Stock News - GuruFocus

Oct 23, 2025
pulisher
Oct 23, 2025

Commentary: A breakthrough to prevent HIV shouldn’t break the bank - The Boston Globe

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead Sciences Rallies 32% in 2025 Are Shares Trading Below Their True Value - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead Sciences (GILD) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Oct 23, 2025
pulisher
Oct 23, 2025

Wolfe Research Adjusts Gilead Sciences Price Target to $140 From $135, Maintains Outperform Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

TD Cowen Adjusts Gilead Sciences Price Target to $125 From $115, Maintains Buy Rating - MarketScreener

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead to present new data on Livdelzi for PBC at Liver Meeting 2025 - Investing.com

Oct 23, 2025
pulisher
Oct 23, 2025

Gilead to present liver disease data at AASLD conference - StreetInsider

Oct 23, 2025
pulisher
Oct 23, 2025

(Seladelpar) in Primary Biliary Cholangitis (PBC) and Investigational Bulevirtide in Chronic Hepatitis Delta - Business Wire

Oct 23, 2025
pulisher
Oct 23, 2025

Using economic indicators to assess Gilead Sciences Inc. potentialJuly 2025 Trade Ideas & Smart Money Movement Alerts - newser.com

Oct 23, 2025
pulisher
Oct 22, 2025

Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance

Oct 22, 2025
pulisher
Oct 22, 2025

CVS (CVS) Delays Adding Gilead's Yeztugo Over Pricing Concerns - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead Sciences (GILD) Halts Phase 1 HIV Treatment Trial - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead discontinues early-stage trial for long-acting injectable for HIV - Seeking Alpha

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead Sciences stock rating reiterated by RBC amid HIV drug setback - Investing.com

Oct 22, 2025
pulisher
Oct 22, 2025

Gilead Sciences (GILD) Halts Phase 1 Study for HIV Treatment - GuruFocus

Oct 22, 2025
pulisher
Oct 22, 2025

CVS Caremark tells AIDS activists Gilead needs to lower the price of its new HIV drug to get on formularies - statnews.com

Oct 22, 2025
pulisher
Oct 22, 2025

What to Expect From Gilead Sciences' Next Quarterly Earnings Report - Barchart.com

Oct 22, 2025
pulisher
Oct 22, 2025

Exit strategy if you’re trapped in Gilead Sciences Inc.Quarterly Investment Review & Low Risk Investment Opportunities - newser.com

Oct 22, 2025
pulisher
Oct 22, 2025

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - GlobeNewswire Inc.

Oct 22, 2025
pulisher
Oct 22, 2025

How to build a dashboard for Gilead Sciences Inc. stockJuly 2025 Pullbacks & Verified Momentum Stock Watchlist - newser.com

Oct 22, 2025
pulisher
Oct 22, 2025

Health Canada conditionally approves Gilead Sciences’ Lyvdelzi for PBC - Pharmaceutical Technology

Oct 22, 2025
pulisher
Oct 22, 2025

Is Gilead Sciences Inc. (Common Stock) (GIS0) stock a momentum leaderEarnings Recap Report & Entry Point Confirmation Alerts - newser.com

Oct 22, 2025
pulisher
Oct 21, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock enhance shareholder value2025 Risk Factors & Reliable Breakout Forecasts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Gilead Sciences Inc. outperform the marketDividend Hike & Daily Volume Surge Trade Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Why Gilead Sciences Inc. (Common Stock) (GIS0) stock attracts wealthy investorsEarnings Beat & Free Weekly Watchlist of Top Performers - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock boost dividends furtherMarket Trend Report & Capital Protection Trade Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is Gilead Sciences Inc. stock cheap at current valuationJuly 2025 Price Swings & High Accuracy Trade Signal Alerts - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Gilead agrees not to raise prices on HIV medicines for state AIDS drug programs - statnews.com

Oct 21, 2025
pulisher
Oct 21, 2025

100 Organizations Denounce Gilead on Price Hikes Gutting ADAP - AIDS Healthcare Foundation

Oct 21, 2025
pulisher
Oct 21, 2025

LYVDELZI® (SELADELPAR) RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - BioSpace

Oct 21, 2025
pulisher
Oct 21, 2025

LYVDELZI® RECEIVES HEALTH CANADA APPROVAL FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS - Investing News Network

Oct 21, 2025
pulisher
Oct 21, 2025

AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP - Yahoo Finance

Oct 21, 2025
pulisher
Oct 21, 2025

What makes Gilead Sciences Inc. (Common Stock) (GIS0) stock appealing to growth investorsWeekly Loss Report & Weekly Watchlist of Top Performers - newser.com

Oct 21, 2025
pulisher
Oct 21, 2025

Is Gilead Sciences Inc. (GIS) stock inflation resilientWeekly Trading Summary & Weekly Stock Breakout Alerts - newser.com

Oct 21, 2025
pulisher
Oct 20, 2025

Targets Report: Will Gilead Sciences Inc. (GIS) stock extend growth storyJuly 2025 Chart Watch & Safe Entry Point Alerts - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Is Gilead Sciences Inc. stock bottoming outTrade Analysis Summary & AI Enhanced Market Trend Forecasts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Gilead Sciences (GILD): Assessing Valuation After Major Trodelvy Breast Cancer Breakthrough and HIV Advances - simplywall.st

Oct 20, 2025
pulisher
Oct 20, 2025

Gilead to spotlight new virology data across HIV, viral hepatitis and respiratory diseases at IDWeek 2025 - European AIDS Treatment Group

Oct 20, 2025
pulisher
Oct 20, 2025

How Gilead Sciences Inc. (Common Stock) (GIS0) stock trades after rate cutsEarnings Trend Report & Real-Time Buy Signal Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Gilead Sciences Inc. stock keep outperforming rivalsMarket Growth Summary & Breakout Confirmation Alerts - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Can Gilead Sciences Inc. hit a new high this monthQuarterly Trade Review & Short-Term High Return Strategies - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitAnalyst Downgrade & Smart Allocation Stock Tips - newser.com

Oct 20, 2025
pulisher
Oct 20, 2025

Will Gilead Sciences Inc. (GIS) stock deliver compounding returnsQuarterly Risk Review & Verified Swing Trading Watchlists - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Fed Watch: Is Gilead Sciences Inc. (GIS) stock inflation resilientJuly 2025 Earnings & Low Volatility Stock Recommendations - nchmf.gov.vn

Oct 20, 2025
pulisher
Oct 20, 2025

Aug Shorts: Will Gilead Sciences Inc. (Common Stock) (GIS0) stock announce a stock splitJuly 2025 Catalysts & Expert Curated Trade Setup Alerts - nchmf.gov.vn

Oct 20, 2025

Gilead Sciences Inc Stock (GILD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Gilead Sciences Inc Stock (GILD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Mercier Johanna
Chief Commercial Officer
Oct 15 '25
Sale
118.08
3,000
354,240
110,193
$291.76
price down icon 0.39%
drug_manufacturers_general PFE
$24.76
price up icon 0.36%
drug_manufacturers_general SNY
$51.64
price up icon 4.28%
drug_manufacturers_general NVO
$52.96
price down icon 0.51%
drug_manufacturers_general MRK
$87.49
price up icon 0.36%
Cap:     |  Volume (24h):